| scholarly article | Q13442814 |
| P819 | ADS bibcode | 1995PNAS...92.8200S |
| P356 | DOI | 10.1073/PNAS.92.18.8200 |
| P932 | PMC publication ID | 41124 |
| P698 | PubMed publication ID | 7545296 |
| P5875 | ResearchGate publication ID | 15654412 |
| P50 | author | Joachim Schultze | Q1690457 |
| Gordon J. Freeman | Q27088375 | ||
| Lee M. Nadler | Q117474702 | ||
| P2093 | author name string | J G Gribben | |
| G S Pinkus | |||
| J Daley | |||
| A A Cardoso | |||
| M J Seamon | |||
| P2860 | cites work | Cloning of B7-2: a CTLA-4 Counter-Receptor That Costimulates Human T Cell Proliferation | Q24311763 |
| The CD40 antigen and its ligand | Q28286277 | ||
| Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity | Q34334817 | ||
| Binding of the B cell activation antigen B7 to CD28 costimulates T cell proliferation and interleukin 2 mRNA accumulation | Q34591923 | ||
| Activated T cells induce expression of B7/BB1 on normal or leukemic B cells through a CD40-dependent signal | Q36361532 | ||
| B7 but not intercellular adhesion molecule-1 costimulation prevents the induction of human alloantigen-specific tolerance | Q36362561 | ||
| CD2 is involved in maintenance and reversal of human alloantigen-specific clonal anergy | Q36363970 | ||
| Major histocompatibility complex class II+B7-1+ tumor cells are potent vaccines for stimulating tumor rejection in tumor-bearing mice | Q36364365 | ||
| Activated human B lymphocytes express three CTLA-4 counterreceptors that costimulate T-cell activation | Q36687697 | ||
| The normal and malignant germinal centre | Q40248654 | ||
| Costimulation of T cells for tumor immunity. | Q40385129 | ||
| New strategies for enhancing the immunogenicity of tumors | Q40492275 | ||
| Gene transfer as cancer therapy | Q40519664 | ||
| Tumor immunotherapy: the tumor cell as an antigen-presenting cell | Q40573295 | ||
| MHC class II restricted tumor antigens and the role of CD4+ T cells in cancer immunotherapy | Q40573308 | ||
| Tumor antigens recognized by T lymphocytes | Q40661131 | ||
| The LFA-1 ligand ICAM-1 provides an important costimulatory signal for T cell receptor-mediated activation of resting T cells. | Q41174210 | ||
| Idiotype/granulocyte-macrophage colony-stimulating factor fusion protein as a vaccine for B-cell lymphoma | Q41559182 | ||
| Costimulation of antitumor immunity by the B7 counterreceptor for the T lymphocyte molecules CD28 and CTLA-4 | Q41589138 | ||
| Immunologic purging of marrow assessed by PCR before autologous bone marrow transplantation for B-cell lymphoma | Q41656230 | ||
| CD40 ligand triggered interleukin-6 secretion in multiple myeloma | Q42829079 | ||
| Tumor Rejection After Direct Costimulation of CD8 + T Cells by B7-Transfected Melanoma Cells | Q44615042 | ||
| Naive versus memory CD4 T cell response to antigen. Memory cells are less dependent on accessory cell costimulation and can respond to many antigen-presenting cell types including resting B cells | Q46681487 | ||
| Role of B7-1 in mediating an immune response to myeloid leukemia cells. | Q53464362 | ||
| A new look for the 1990s | Q59087832 | ||
| Purified intercellular adhesion molecule-1 (ICAM-1) is a ligand for lymphocyte function-associated antigen 1 (LFA-1) | Q68202545 | ||
| Expression of B cell activation antigens on normal and malignant B cells | Q70363976 | ||
| Cancer vaccines | Q70477447 | ||
| P433 | issue | 18 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 8200-8204 | |
| P577 | publication date | 1995-08-01 | |
| P1433 | published in | Proceedings of the National Academy of Sciences of the United States of America | Q1146531 |
| P1476 | title | Follicular lymphomas can be induced to present alloantigen efficiently: a conceptual model to improve their tumor immunogenicity | |
| P478 | volume | 92 |
Search more.